Browsing Artikler, rapporter og annet (farmasi) by Author "Fleten, Karianne Giller"

Now showing items 1-2 of 2

    • Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors 

      Vasiliauskaite, Kotryna; Fleten, Karianne Giller; Barkovskaya, Anna; Nygaard, Vigdis; Haugen, Mads Haugland; Engesæter, Birgit Øvstebø; Mælandsmo, Gunhild; Prasmickaite, Lina (Journal article; Tidsskriftartikkel; Peer reviewed, 2016)
      The knowledge on how tumor-associated stroma influences efficacy of anti-cancer therapy just started to emerge. Here we show that lung fibroblasts reduce melanoma sensitivity to the BRAF inhibitor (BRAFi) vemurafenib only if the two cell types are in close proximity. In the presence of fibroblasts, the adjacent melanoma cells acquire de-differentiated mesenchymal-like phenotype. Upon treatment with ...

    • Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer 

      Fleten, Karianne Giller; Eksteen, Johannes J.; Mauseth, Brynjar; Camilio, Ketil André; Vasskog, Terje; Sveinbjørnsson, Baldur; Rekdal, Øystein; Mælandsmo, Gunhild Mari; Flatmark, Kjersti (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-03-24)
      Oncolytic peptides represent a novel, promising cancer treatment strategy with activity in a broad spectrum of cancer entities, including colorectal cancer (CRC). Cancer cells are killed by immunogenic cell death, causing long-lasting anticancer immune responses, a feature of particular interest in non-immunogenic CRC. Oncolytic peptides DTT-205 and DTT-304 were administered by intratumoral injection ...